Pharmarise Holdings Corp. (JP:2796)
:2796
Top Page
Pharmarise Holdings Corp.
(2796)
Select Model
Select Model
Rating:48Neutral
Price Target:
¥520.00
▼(-0.19% Downside)
Action:ReiteratedDate:10/17/25
The overall score of 48 for Pharmarise Holdings Corp. is primarily driven by weak financial performance, with persistent losses and high leverage posing significant risks. Technical indicators provide some optimism with an upward price trend, but negative valuation metrics due to unprofitability further weigh on the score.
Positive Factors
Revenue Growth
The company's moderate revenue growth indicates a solid market position and ability to expand its customer base, supporting long-term business sustainability.
Negative Factors
High Leverage
High leverage can limit financial flexibility and increase risk during economic downturns, potentially impacting long-term growth and stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The company's moderate revenue growth indicates a solid market position and ability to expand its customer base, supporting long-term business sustainability.
Read all positive factors
Pharmarise Holdings Corp. (2796) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.08B
Dividend Yield2.65%
Average Volume (3M)15.55K
Price to Earnings (P/E)―
Beta (1Y)0.19
Revenue Growth15.66%
EPS Growth56.93%
CountryJP
Employees1,848
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)13.70
Shares Outstanding12,060,381
10 Day Avg. Volume9,170
30 Day Avg. Volume15,546
Financial Highlights & Ratios
PEG Ratio5.35
Price to Book (P/B)0.80
Price to Sales (P/S)0.09
P/FCF Ratio8.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pharmarise Holdings Corp. Business Overview & Revenue Model
Company Description
Pharmarise Holdings Corporation manages dispensing pharmacies in Japan. Its dispensing pharmacies provide patients with dispensing services based on prescriptions drawn up by medical institutions. The company also manages drug stores and convenien...
How the Company Makes Money
Pharmarise Holdings Corp. generates revenue primarily through the sale of its pharmaceutical products, including both prescription medications and over-the-counter drugs. The company's revenue model includes direct sales to healthcare providers, h...
Pharmarise Holdings Corp. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
40
Negative
Cash Flow
55
Neutral
| Breakdown | TTM | May 2024 | May 2023 | May 2022 | May 2021 | May 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 65.03B | 63.51B | 54.47B | 52.03B | 51.61B | 52.32B |
| Gross Profit | 8.29B | 8.20B | 7.89B | 7.50B | 7.42B | 7.33B |
| EBITDA | 1.92B | 1.79B | 2.09B | 2.66B | 2.83B | 2.59B |
| Net Income | -256.00M | -368.00M | -351.00M | 333.00M | 448.00M | 425.00M |
Balance Sheet | ||||||
| Total Assets | 30.17B | 31.99B | 29.54B | 23.46B | 23.78B | 24.72B |
| Cash, Cash Equivalents and Short-Term Investments | 2.12B | 4.91B | 7.15B | 4.74B | 3.99B | 4.60B |
| Total Debt | 13.03B | 14.28B | 12.75B | 9.14B | 9.91B | 10.70B |
| Total Liabilities | 23.53B | 25.07B | 22.10B | 16.47B | 17.08B | 18.39B |
| Stockholders Equity | 6.62B | 6.87B | 7.36B | 6.88B | 6.61B | 6.22B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 674.00M | 2.24B | 2.14B | 334.00M | 1.44B |
| Operating Cash Flow | 0.00 | 1.31B | 2.71B | 2.52B | 713.00M | 1.95B |
| Investing Cash Flow | 0.00 | -4.46B | -3.12B | -703.00M | -292.00M | -1.08B |
| Financing Cash Flow | 0.00 | 939.00M | 2.77B | -1.07B | -1.03B | -728.00M |
Pharmarise Holdings Corp. Technical Analysis
Positive
521.00
Price Trends
515.92
Positive
520.10
Negative
514.49
Positive
Market Momentum
-0.19
Negative
53.11
Neutral
80.56
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2796, the sentiment is Positive. The current price of 521 is above the 20-day moving average (MA) of 512.85, above the 50-day MA of 515.92, and above the 200-day MA of 514.49, indicating a bullish trend. The MACD of -0.19 indicates Negative momentum. The RSI at 53.11 is Neutral, neither overbought nor oversold. The STOCH value of 80.56 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:2796.
Pharmarise Holdings Corp. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ¥16.75B | 6.83 | ― | 2.32% | 6.60% | 27.97% | |
64 Neutral | ¥44.58B | 10.10 | ― | 2.53% | 2.74% | -7.19% | |
63 Neutral | ¥41.60B | 239.59 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥18.74B | 14.56 | ― | 1.83% | 4.30% | 52.38% | |
48 Neutral | ¥6.08B | -12.09 | ― | 2.65% | 15.66% | 56.93% | |
47 Neutral | ¥9.25B | -6.49 | ― | ― | ― | ― |
* Healthcare Sector Average
JP:2796
Pharmarise Holdings Corp.
518.00
58.43
12.71%
JP:3417
Ohki Health Care Holdings, Inc.
1,359.00
610.91
81.66%
JP:4350
Medical System Network Co., Ltd.
555.00
176.00
46.44%
JP:4931
Shinnihonseiyaku Co., Ltd.
2,083.00
-162.60
-7.24%
JP:190A
Chordia Therapeutics Inc.
130.00
-129.00
-49.81%
JP:219A
Heartseed, Inc.
1,820.00
-228.00
-11.13%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.